Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay

Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay
  • Biocept Inc BIOC has announced new data from a study assessing its cerebrospinal fluid assay, CNSide.
  • Data showed that CNSide detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis.
  • The study will be presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology.
  • Related: Biocept Collaborates With Quest Diagnostics For Liquid Biopsy Testing For Lung Cancer Patients.
  • An estimated 3-9% of NSCLC diagnosed patients develop leptomeningeal carcinomatosis (LMC), a complication in which cancer spreads to the membranes surrounding the brain and spinal cord. 
  • Huntsman Cancer Institute used Biocept's CNSide assay to detect and analyze tumor cells in the cerebrospinal fluid of 15 patients. 
  • Of the samples analyzed, CNSide detected tumor cells in 100% of samples with LMC, while cytology detected tumor cells in just 40% of the samples. 
  • CNSide also identified actionable biomarkers in tumor cells, which allowed oncologists to make targeted treatment decisions. 
  • The study results suggest that CNSide is more sensitive than cytology.
  • Price Action: BIOC shares are up 5.16% at $3.72 during the market session on the last check Thursday.
Posted In: BriefsDiagnosticsLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneral